Money Concepts Capital Corp Has $475,000 Stock Holdings in GSK plc (NYSE:GSK)

Money Concepts Capital Corp cut its holdings in GSK plc (NYSE:GSK) by 9.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 14,054 shares of the pharmaceutical company’s stock after selling 1,502 shares during the quarter. Money Concepts Capital Corp’s holdings in GSK were worth $475,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC grew its position in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its position in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Primecap Management Co. CA boosted its position in GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after acquiring an additional 342,365 shares during the last quarter. Provident Trust Co. boosted its position in GSK by 1.7% during the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after acquiring an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC boosted its position in GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Down 3.5 %

NYSE GSK opened at $36.38 on Friday. The company has a market cap of $75.39 billion, a PE ratio of 23.62, a PEG ratio of 1.38 and a beta of 0.64. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The stock has a 50 day moving average of $34.17 and a 200-day moving average of $37.60.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. On average, equities research analysts anticipate that GSK plc will post 3.92 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.32%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 92.45%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GSK. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.